Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.

Rheumatology (Oxford) · 2025 · PMC11879290 · PMID 38652570

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nearly significantno p-value reported

mRSS at week 48 decreased by 6.1 points in the faSScinate trial, vs a nearly significant change compared with the placebo group (4.4).

also in 3,287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.